Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

Cancer

Volumn 106, Issue 10, 2006, Pages 2095-2103

  Cataliotti, Luigi ^a   Buzdar, Aman U ^b   Noguchi, Shinzaburo ^c   Bines, Jose ^d   Takatsuka, Yuichi ^e   Petrakova, Katarina ^f   Dube, Pierre ^g   De Oliveira, Celia Tosello ^h  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e KANSAI ROSAI HOSPITAL   (Japan)

^f MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^g MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^h Institute Brasileiro de Combate ao Cancer   (Brazil)

Author keywords

Anastrozole; Breast cancer; Estrogen receptor; Hormone receptor; Neoadjuvant; Postmenopausal; Preoperative; Tamoxifen; Tumor reduction

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FATIGUE; FEMALE; HEADACHE; HORMONE RECEPTOR POSITIVE BREAST CANCER; HOT FLUSH; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR SIZE REDUCTION; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; ODDS RATIO; POSTMENOPAUSE; PREOPERATIVE CARE; RECEPTORS, ESTROGEN; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 33646371731     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21872     Document Type: Article

References (26)

1. Anderson ED, Forrest AP, Levack PA, et al. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989;60:223-226.
2. Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. Cancer Control. 2000;7:557-562.
3. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600-2608.
4. Preece PE, Wood RA, Mackie CR, et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982;2804:869-870.
5. Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin Cancer Res. 2001;7:4388s-4391s.
6. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493.
7. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
8. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease [abstract 132]. Proc Am Soc Clin Oncol. 2002;21:34a.
9. Jakesz R, for the the ABCSG. Comparison of pre vs postoperative chemotherapy in breast cancer patients. Four-year results of Austrian Breast Colorectal Cancer Study Group (ABCSG) Trial 7 [abstract 125]. Proc Am Soc Clin Oncol. 2001;20:32a.
10. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A:645-652.
11. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001;2:561-570.
12. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-4237.
13. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in post-menopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2000;6:2229-2235.
14. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527-1532.
15. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-3816.
16. Harper-Wynne CL, Sacks NP, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol. 2002;20:1026-1035.
17. Mansi JL, Smith IE, Walsh G, et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol. 1989;25:1623-1627.
18. Milla-Santos A, Milla I, Rallo L, et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts) [abstract 156]. Proc Am Soc Clin Oncol. 2002;21:40a.
19. Semiglazov V, Semiglazov W, Ivanov VG, et al. Anastrozole (A) vs tamoxifen (T) vs combine (A + T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Breast. 2003;12:S39-S87.
20. Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6- dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 1991;64:887-894.
21. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 1993;53:266-270.
22. Johnston SR, Smith IE, Doody D, et al. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 1994;54:5875-5881.
23. Anderson TJ, Dixon JM, Stuart M, et al. Effect of neoadjuvant treatment with anastrozole on tumour histology in post-menopausal women with large operable breast cancer. Br J Cancer. 2002;87:334-338.
24. World Health Organization. WHO Classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer (IARC) Press; 2002.
25. Buzdar A, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer. 2002;95:2006-2016.
26. Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005;23:24-29.